Investigational Device Exemption (IDE) for the development of Adagloxad Simolenin (OBI-822) was approved by the US Food and Drug Administration (FDA) for its use in OBI-822 Phase III Clinical Trial
2018.Jul.08
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
2018.Jun.27
Announcement on the board resolution at Annual General Meeting 2018
2018.May.16
Amendment on the announcement for 2018 Annual General Meeting (discussion notes)
2018.May.11
The board of directors of the company resolved to request the shareholders to authorize the board of directors to handle cash-increase of common shares to issue overseas depository receipts
2018.May.11
The board of directors of the company resolved to request the shareholders to authorize the board of directors to handle private placement of common shares at the Annual General Meeting
2018.May.11
Amendment on the announcement for 2018 Annual General Meeting
2018.May.11
Announcement of change of accountant due to internal adjustment of the accounting firm
2018.Apr.20
Announcement based on the procedures for acquisition or disposal of assets
2018.Apr.19
FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors
